CorMedix Inc. Reports Q1 2026 Earnings with Revenue Growth and Updated Guidance
CorMedix reported first-quarter net revenue of $127.4 million, driven by sustained demand for DefenCath and the full contribution from its Melinta portfolio acquisition. The company raised its annual revenue guidance to between $325 million and $345 million.
Tickers: $CRMD
Topics: acquisition guidance pipeline revenue tdapa_reimbursement